Gilead Sciences Inc (GILD)
Debt-to-equity ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | 23,189,000 | 22,957,000 | 25,179,000 | 28,645,000 | 22,094,000 |
| Total stockholders’ equity | US$ in thousands | 22,833,000 | 21,240,000 | 21,069,000 | 18,202,000 | 22,525,000 |
| Debt-to-equity ratio | 1.02 | 1.08 | 1.20 | 1.57 | 0.98 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $23,189,000K ÷ $22,833,000K
= 1.02
The debt-to-equity ratio of Gilead Sciences, Inc. has fluctuated over the past five years. In 2019 and 2023, the company had a debt-to-equity ratio of 1.09, indicating an equal proportion of debt and equity in its capital structure. However, in 2020, the ratio increased to 1.73, suggesting a higher level of debt relative to equity in that year.
Subsequently, the ratio decreased to 1.27 in 2021 and further to 1.19 in 2022, indicating a gradual improvement in the company's debt position relative to its equity. Overall, the trend in the debt-to-equity ratio of Gilead Sciences, Inc. shows some variability but also a general trend towards a lower reliance on debt financing compared to equity over the analyzed period.
Peer comparison
Dec 31, 2023